Complete remission with romidepsin in a patient with T-cell acute lymphoblastic leukemia refractory to induction hyper-CVAD.

about

Complete remission with romidepsin in a patient with T-cell acute lymphoblastic leukemia refractory to induction hyper-CVAD.

Item

http://www.wikidata.org/entity/Q48353504

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Complete remission with romide ...... ctory to induction hyper-CVAD.

@en

Complete remission with romide ...... ctory to induction hyper-CVAD.

@nl

type

Item

label

Complete remission with romide ...... ctory to induction hyper-CVAD.

@en

Complete remission with romide ...... ctory to induction hyper-CVAD.

@nl

prefLabel

Complete remission with romide ...... ctory to induction hyper-CVAD.

@en

Complete remission with romide ...... ctory to induction hyper-CVAD.

@nl

P1476

Complete remission with romide ...... ctory to induction hyper-CVAD.

@en

P2093

John Carson

http://www.w3.org/2001/XMLSchema#string

P2860

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801.

Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.

Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International

Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study.

Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses

Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia

T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993)

Romidepsin targets multiple survival signaling pathways in malignant T cells

Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype.

T-cell lymphoblastic lymphoma and T-cell acute lymphoblastic leukemia: a separate entity?

P304

340-343

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.1002/HON.2421

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Mark W Brunvand

P577

2017-05-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28560733

http://www.w3.org/2001/XMLSchema#string

P932

5836898

http://www.w3.org/2001/XMLSchema#string